These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20658288)

  • 21. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
    Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
    Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
    Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
    J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
    Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
    Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.
    Mamot C; Ritschard R; Wicki A; Küng W; Schuller J; Herrmann R; Rochlitz C
    J Drug Target; 2012 Jun; 20(5):422-32. PubMed ID: 22519893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells.
    Du G; Lin H; Wang M; Zhang S; Wu X; Lu L; Ji L; Yu L
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):277-87. PubMed ID: 19466611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxidative Stress Promotes Doxorubicin-Induced Pgp and BCRP Expression in Colon Cancer Cells Under Hypoxic Conditions.
    Pinzón-Daza ML; Cuellar-Saenz Y; Nualart F; Ondo-Mendez A; Del Riesgo L; Castillo-Rivera F; Garzón R
    J Cell Biochem; 2017 Jul; 118(7):1868-1878. PubMed ID: 28106284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mad1 mediates hypoxia-induced doxorubicin resistance in colon cancer cells by inhibiting mitochondrial function.
    Cho K; Shin HW; Kim YI; Cho CH; Chun YS; Kim TY; Park JW
    Free Radic Biol Med; 2013 Jul; 60():201-10. PubMed ID: 23459071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel cancer therapy: combined liposomal hypoxia inducible factor 1 alpha antisense oligonucleotides and an anticancer drug.
    Wang Y; Minko T
    Biochem Pharmacol; 2004 Nov; 68(10):2031-42. PubMed ID: 15476674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypoxia promotes nuclear translocation and transcriptional function in the oncogenic tyrosine kinase RON.
    Chang HY; Liu HS; Lai MD; Tsai YS; Tzai TS; Cheng HL; Chow NH
    Cancer Res; 2014 Aug; 74(16):4549-62. PubMed ID: 24903148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Impact of RNA interference targeting hypoxia-inducible factor-1alpha on chemosensitivity in esophageal squamous cell carcinoma cells under hypoxia].
    Wu XA; Sun Y; Fan QX; Wang LX; Wang RL; Zhang L
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(37):2640-4. PubMed ID: 18162154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxic tumor therapy by hemoglobin-mediated drug delivery and reversal of hypoxia-induced chemoresistance.
    Yang J; Li W; Luo L; Jiang M; Zhu C; Qin B; Yin H; Yuan X; Yin X; Zhang J; Luo Z; Du Y; You J
    Biomaterials; 2018 Nov; 182():145-156. PubMed ID: 30121013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-Delivery of Metformin Enhances the Antimultidrug Resistant Tumor Effect of Doxorubicin by Improving Hypoxic Tumor Microenvironment.
    Li Y; Luo J; Lin MT; Zhi P; Guo WW; Han M; You J; Gao JQ
    Mol Pharm; 2019 Jul; 16(7):2966-2979. PubMed ID: 31095914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bifunctional liposomes reduce the chemotherapy resistance of doxorubicin induced by reactive oxygen species.
    Xu L; Zhang Z; Ding Y; Wang L; Cheng Y; Meng L; Wu J; Yuan A; Hu Y; Zhu Y
    Biomater Sci; 2019 Nov; 7(11):4782-4789. PubMed ID: 31524211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin.
    Mei L; Liu Y; Zhang Q; Gao H; Zhang Z; He Q
    J Control Release; 2014 Dec; 196():324-31. PubMed ID: 25450404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
    Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
    Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells.
    Merighi S; Benini A; Mirandola P; Gessi S; Varani K; Simioni C; Leung E; Maclennan S; Baraldi PG; Borea PA
    Mol Pharmacol; 2007 Aug; 72(2):395-406. PubMed ID: 17488804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
    Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.